Skip to main content

Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients

Ticagrelor has been proved to be more effective than clopidogrel; however, little is known about the switching between ticagrelor and clopidogrel in real-world clinical practice. We assessed the prevalence, related factors, dose bridging, compliance, and short-term outcomes of in-hospital switching between ticagrelor and clopidogrel in consecutively recruited patients treated by ticagrelor after percutaneous coronary intervention (PCI). A total of 417 eligible patients administrated with ticagrelor in-hospital after PCI were recruited. Switching between ticagrelor and clopidogrel occurred in 362 (86.8%) patients, with 318 (76.3%) from clopidogrel to ticagrelor occurring mainly after PCI and 44 (10.6%) from ticagrelor to clopidogrel primarily at discharge. History of cerebrovascular disease, final diagnosis of acute coronary syndrome, left main disease, ostial lesion, co-administration with warfarin, CYP2C19 loss-of-function alleles’ carriage status, and ticagrelor-related dyspnoea emerged as related factors for the switching between clopidogrel and ticagrelor. Dose bridging between clopidogrel loading dose and ticagrelor maintenance dose (MD) was more frequent in patients switching from clopidogrel to ticagrelor, while the bridging between ticagrelor MD and clopidogrel MD was more likely to occur in patients switched from ticagrelor to clopidogrel. At 6 month follow-up, poor compliance was observed in patients from clopidogrel to ticagrelor (64.8%) or treated only by ticagrelor (50.9%), but perfect compliance in patients from ticagrelor to clopidogrel (100%). After excluding the cases with incompliance, patients switching from ticagrelor to clopidogrel had a relatively lower bleeding risk in comparison with patients with constant ticagrelor treatment and those switching from clopidogrel to ticagrelor (29.5% vs. 50.0% vs. 46.6%, adjusted P = 0.02). In-hospital switching between ticagrelor and clopidogrel is frequent in patients undergoing PCI. In comparison with constant ticagrelor treatment, switching from clopidogrel to ticagrelor in ischaemic high-risk patients confers similar antiplatelet efficacy and safety, while switching from ticagrelor to clopidogrel in ischaemic low-risk patients relates to lower hazard for bleeding events.



from European Heart Journal Supplements - current issue http://ift.tt/1WfT68T
via IFTTT

Popular posts from this blog

Photo

from Bodybuilding Motivation http://ift.tt/2EtKRn5 via IFTTT

Hany Rambod's Ultimate Guide To FST-7

What do the bodybuilding greats of our time all have in common? A style of training that showed them the limitless potential of their physique. Here's what you need to know about FST-7. Hany Rambod's nickname is "The Pro Creator." He's watched his protégés take home the ultimate prize at the Olympia Weekend 15 times—including three on a single night in 2014. Far more times than that, he's watched his clients push their already impressive physiques where they never thought possible. The way he did it is no mystery. Rambod's clients all followed FST-7, or "fascia-stretch training," his signature training style. Do it right, and it can substantially change both the size and shape of your muscles. Just don't expect it to be easy or painless. If you've wondered what all the fuss is about, Rambod has created a video explaining the fundamentals of FST-7, along with tips on how to scale it for everyone from beginners to advanced lifters and h...